Methylphenidate
- TRADE NAMES: Centedrin; Concerta (Janssen); Cotempla; Daytrana; Metadate CD (Celltech); Methylin (Mallinckrodt); Rilatine; Ritalin (Novartis); Rubifen
- INDICATIONS: Attention deficit disorder, narcolepsy
- CLASS: Amphetamine, Anti-attention deficit hyperactivity disorder (anti-ADHD)
- HALF-LIFE: 2–4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amitriptyline, Benazepril, Bupropion, Captopril, Citalopram, Clevidipine, Cyclosporine, Enalapril, Escitalopram, Irbesartan, Linezolid, Lisinopril, Lurasidone, MAO inhibitors, Olmesartan, Paliperidone, Pantoprazole, Paroxetine Hydrochloride, Phenylbutazone, Pimozide, Quinapril, Safinamide, Ziprasidone
PREGNANCY CATEGORY: C
ABUSE AND DEPENDENCE
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric